Skip to main content
Quest Diagnostics Home
Contact a representative Download white paper
Call
Menu

The need for personalized prescribing and dosing strategies is growing

2M

Adverse drug reactions (ADRs) occur annually in the US1

20%

Of patients in the US take multiple medications and many are taking 5 or more2

4th

Adverse drug interactions (ADIs) are the 4th leading cause of death in the US3

Genetic impact on prescribing strategies

Genetic variations can impact drug efficacy and response leading to added expenses for health systems

Variants in specific genes can significantly alter how a drug is absorbed, activated, or broken down—leading to reduced efficacy or increased risk of adverse effects. 

 

Pharmacogenomics offers an opportunity for safer and more efficient pharmacotherapy—minimizing trial-and-error prescribing while improving outcomes and reducing costly hospital admissions.4

Contact a representative See how PGx works
PGx-Sprint-Support_What-is-PGx.

Pharmacogenomic testing value

Help reduce costs, improve outcomes, and maximize genetic insights across specialties

With over 20% of patients in the US taking multiple medications, the potential for unnecessary costs and complications from trial-and-error prescribing is significant, making precise prescribing decisions essential. Pharmacogenetics testing solutions from Quest Diagnostics analyze 21 key genes that affect drug metabolism and efficacy. We can identify key gene-drug associations that may change how physicians create drug regimens. Leveraging these insights can help create more tailored regimens that may work better for patients.

 

This opportunity for increased personalization not only helps avoid adverse drug reactions that may interfere with treatment adherence but also helps reduce costly hospitalizations, readmissions, and wasted prescriptions. Additionally, a single pharmacogenomics test provides genetic insights that can be applied across multiple clinical specialties, unlocking value far beyond a single prescribing decision.

Contact a representative Discover savings
PGx-cost-savings-graph

Pharmacogenomic insights can drive individualized treatment choices and help improve outcomes

Our pharmacogenomics panels analyze clinically actionable genes known to influence drug metabolism. Because PGx testing analyzes germline DNA, the results remain valid for life.5 As medication regimens evolve, the information provided can support safer prescribing decisions at every stage of care. Combined with clinical judgment and patient-specific factors, PGx testing provides a foundation for more informed, personalized treatment, potentially avoiding adverse drug reactions and preventing costly rehospitalizatous.

A study has shown PGx-guided dosing can reduce adverse drug interaction (ADI) by 30%6

Approximately 18% of approved therapies have a clinically actionable PGx association7

Greater than 90% of patients will have at least 1 clinically actionable genetic variant8

Testing that drives whole patient care for your health system

 

Our pharmacogenomics offerings analyze genes with clinically actionable pharmacogenetic associations supported by insights from expert groups like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and ClinPGx. A single test can inform decisions across a broad range of clinical areas.

 

EMR integration allows practitioners to "test once, utilize repeatedly” efficiencies, especially when more comprehensice, cross-clinical panels are used, rather than narrowly targeted ones. Having this information early in a patient's tratment journey can lead to cost-efficiencies and shorten the time to reach optimal dosing with the right drug.

cross-clinical-polypharmacy-approach-infographic

Realize the value of pharmacogenomic testing for health systems

Let's discuss how we can support your health system's prescribing strategies.

843

* indicates required

Some images may feature models and are intended for illustrative purposes only.

  1. FDA. Qlik sense. fis.fda.gov. https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis
  2. Jacobson A. Prescription drug statistics 2021. The Checkup. Published September 1, 2021. https://www.singlecare.com/blog/news/prescription-drug-statistics
  3. Research C for DE and. Preventable Adverse Drug Reactions: A Focus on Drug Interactions. FDA. Published online January 20, 2020. https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions
  4. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186-200. doi:10.1046/j.1365-2796.2001.00879.x
  5. Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(4):301-312. doi:10.1038/tpj.2016.11
  6. Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet (London, England). 2023;401(10374):347-356. Doi:https://doi.org/10.1016/S0140-6736(22)01841-4 
  7. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine. 2001;250(3):186-200. doi:10.1046/j.1365-2796.2001.00879.x
  8. Chanfreau-Coffinier C, Hull LE, Lynch JA, et al. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. JAMA Netw Open. 2019;2(6):e195345. doi:10.1001/jamanetworkopen.2019.5345

Our company

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.